Biolegend, 637754, Ultra-LEAF™ Purified anti-mouse CD152 Antibody, 1mg

Mouse CTLA-4 was initially identified by differential screening of a murine cytolytic cDNA library. It is a member of the IgG superfamily, and it encodes a 223 amino acid protein and possesses a single extracellular V domain, a transmembrane domain, and a cytoplasmic domain. CTLA-4 is ~30% homologous with CD28, and both bind to the same ligands (B7.1/CD80 and B7.2/CD86) although CTLA-4 binds with higher affinity than CD28. Parallel recognition of a specific MHC-peptide complex by the T-cell receptor and CD80 or CD86 by the costimulatory receptor CD28 results in T cell activation, cytokine production, proliferation, and differentiation. After the T cell activation process and upregulation of CTLA-4, co-ligation of the TCR to MHC-peptide complex and CTLA-4 to its ligands results in cell cycle arrest and the end to T cell activation. It has been suggested that the negative regulatory mechanism of CTLA-4 is mediated through trans-endocytosis of CD80 and CD86 (capture of ligands from opposing cells). The ligands are removed from the original cell and degraded inside of CTLA-4-expressing cells. As a result, the action of CD28 is impaired. Alternative splice variants of CTLA-4 have been described in mice and humans; these variants skip exon 2 (ligand-binding domain) or exon 3 (transmembrane domain). The ligand independent CTLA-4 is expressed in mice, but not in humans, and the soluble CTLA-4 (sCTLA-4) is expressed in mice and humans. CTLA-4 is constitutively expressed by Tregs, and they are an important source of sCTLA-4. It has been suggested that sCTLA-4 potentiates regulatory T cell function. High levels of sCTLA-4 in Tregs have been associated with type 1 diabetes (T1D) and other autoimmune diseases.
1mg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: Recombinant Mouse CTLA-4-Fc Chimera
Formulation: 0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
Endotoxin Level: Less than 0.01 EU/μg of the protein (< 0.001 ng/μg of the protein) as determined by the LAL test
Preparation: The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration: The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Application: Block - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by blocking the binding of 0.05 µg/mL recombinant biotinylated mouse (CTLA-4)-Fc (Cat. No. 779102) to immobilized 1 µg/mL recombinant mouse CD86-FC chimera (Cat. No. 771704). ND50 range: 0.01 - 0.06 µg/mL. It is recommended that the reagent be titrated for optimal performance for each application.
RRID: AB_3106186 (BioLegend Cat. No. 637753) AB_3106186 (BioLegend Cat. No. 637754)
Structure: Disulfide-linked homodimer, biotinylated via amines
Distribution: Activated T cells, CD4, CD8, and Tregs
Function: Inhibits T cell activation by reducing IL-2 production and IL-2R expression, also arresting T cells in G1 phase of the cell cycle; protects against the development of autoimmunity
Interaction: Antigen presenting cells, B cells
Ligand/Receptor: CD80 (B7.1), CD86 (B7.2)
Cell Type: B cells, T cells, Tregs
Biology Area: Immunology
Molecular Family: CD Molecules, Immune Checkpoint Receptors
Antigen References: Linsley PS, et al. 1991. J Exp Med. 174:561-9. Pentcheva-Hoang T, et al. 2004. Immunity. 2:401-13. Qureshi OS, et al. 2011. Science. 332:600-3. Gerold KD, et al. 2011. Diabetes. 60:1955-63. Ryden A, et al. 2012. Diabetes Metab. Res. Rev. 28:84-96. Mittal AK, et al 2013. PloS One. 8:e70352. Ward FJ, et al. 2013. Eur J Immunol. 43:1274-85.
Gene ID: 12477
UniProt: View information about CD152 on UniProt.org
Clone: A21140B
Regulatory Status: RUO
Other Names: Cytotoxic T-lymphocyte protein 4, Otal4, CTLA-4, Cytotoxic T-lymphocyte-associated
Isotype: Rat IgG1, κ
Q: Do you guarantee that your antibodies are totally pathogen free?
A: BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.
Q: Does BioLegend test each Ultra-LEAF™ antibody by functional assay?
A: No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.
Q: Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?
A: No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.
Q: Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?
A: We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.